tiprankstipranks
Trending News
More News >

Eupraxia Pharmaceuticals initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $12 price target Eupraxia has the potential for a best in class treatment for the “ever-growing” eosinophilic esophagitis market, the analyst tells investors in a research note. The firm says the company has shown the potential for an annual treatment of EP-104GI in this condition, which could grow to a 1M addressable patient market.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1